Roflupram exerts neuroprotection via activation of CREB/PGC-1α signalling in experimental models of Parkinson's disease.

Jiahong ZhongWenli DongYunyun QinJinfeng XieJiao XiaoJiangping XuHai-Tao Wang

Published in: British journal of pharmacology (2020)

Roflupram protected dopaminergic neurons from apoptosis via the CREB/PGC-1α pathway in PD models. Hence, roflupram has potential as a protective drug in the treatment of PD.